COVID-19: Our series of regulatory legislation trackers for the Life Sciences & Healthcare industry

Regulatory 1 min
May 7, 2020

COVID-19 presents an unprecedented challenge to the global life sciences industry.  Members of our International Life Sciences & Healthcare team, lawyers who have a wealth of hands-on experience and strong relationships with regulatory bodies, have worked together to provide an update in the form of a Q&A for each of the countries we are located.  This update aims to provide guidance on the responses of EU and Asia-Pac regulators in the areas of clinical trials, medical devices, market access, public procurement and compulsory licensing.

Today we release the latest in our series, focusing on Public Procurement, watch this space for the others coming very soon!

  • COVID-19: Legislation Tracker for Medical Devices, read here
  • COVID-19: Legislation Tracker for Clinical Trials, read here
  • COVID-19: Legislation Tracker for Public Procurement, read here
  • COVID-19: Legislation Tracker for State Use/Compulsory Licensing, read here

Related articles

Worldwide Interpol operation Pangea XIV leads to shutdowns and arrests
Operation Pangea is a yearly recurring operation in which Interpol aims to remove the online sale of...
A vaccine for COVID 19 –risks and liabilities in international perspective
As the development of vaccines against COVID-19 is progressing, the question becomes urgent who will...
Processing health data in France: What to look out for after GDPR?
French law imposes stricter requirements than the General Data Protection Regulation (“GDPR”) regarding...
Cookie consent
We use analytics cookies to help us understand if our website is working well and to learn what content is most useful to visitors. We also use some cookies which are essential to make our website work. You can accept or reject our analytic cookies (including the collection of associated data) and change your mind at any time. Find out more in our Cookie Notice.